About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Microbiome Research’s group seeks to investigate the role of the microbiota in health and disease. Its secondary objectives include developing molecular as well as bioinformatics tools to characterize the microbiome structure and function, discovering micro-biomarkers for diagnosis and prognosis, investigating how fecal microbiota transplantation could be used as a therapeutic strategy, and evaluating the impact of diet on the gut microbial ecosystem The Microbiome Lab is a multidisciplinary team, composed of molecular biologists, bioinformaticians, and physicians. The group tackles several clinical fields including inflammatory bowel diseases, diabetes, liver diseases, pre-term birth, and critical illness.
IP: Susana Clemente Bautista Collaborators: Maria José Cabañas Poy, Oscar Segarra Canton, Marina Álvarez Beltrán, Sonia García García Funding agency: Sociedad Española de Farmacia Hospitalaria Funding: 6240 Reference: 2021/SEFH/FARMACIA/CLEMENTE Duration: 06/09/2022 - 31/12/2024
IP: Chaysavanh Manichanh Collaborators: Zaida Soler Luque, Evaluate the effect of diet on the gut microbial community Funding agency: Instituto de Salud Carlos III Funding: 119567 Reference: FI21/00262 Duration: 01/01/2022 - 31/12/2025
IP: Chaysavanh Manichanh Collaborators: Claudia Maria Herrera de Guise, Natalia Borruel Sainz, Francesc Casellas Jordá, Isaac Manjon Fernández Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI20/00130 Duration: 01/01/2021 - 31/12/2024
The results show that diet induces changes in the gut microbiota that differ between Crohn’s disease and ulcerative colitis, and that influence levels of intestinal inflammation.
The study, involving a thousand participants from different regions of Spain, shows that diet influences the diversity and composition of the microbiota and, therefore, health.
The study also linked improved microbiota diversity to better liver function.
Check the current rates of the services offered by the Microbiome Research group
We are looking for volunteers who wish to participate in a study on dietary habits, microbiota and immune system.
